Jim Cramer on Johnson & Johnson: “I Think It’s a Terrific Entry Point”

Group 1 - Johnson & Johnson is planning to spin off its orthopaedics business, DePuy Synthes, which is expected to raise its price-to-earnings multiple due to slower growth compared to its core pharmaceutical franchise [1] - The company previously spun off Kenvue, its over-the-counter drug business, which also positively impacted its valuation [1] - The stock experienced a decline of more than $5 in a single day, presenting a potential entry point for investors [1] Group 2 - Johnson & Johnson develops and sells a range of healthcare products, including pharmaceuticals and medical technologies, with a focus on various therapeutic areas such as immunology, oncology, and cardiovascular care [2] - The company is recognized for its strong franchises, and there is a particular interest in its current strategy of spinning off its commoditized artificial joint business [2]